Algorithmiq

About

Algorithmiq develops quantum algorithms and software for drug discovery and pharmaceutical research, focusing on quantum-enhanced molecular simulation and optimization techniques to accelerate the development of new medicines by solving complex computational problems in chemistry and biology that are intractable for classical computers. In February 2025, Algorithmiq partnered with Quantum Circuits to leverage the Aqumen Seeker full-stack quantum computing system featuring industry-first dual-rail qubits with built-in error detection for more accurate chemistry calculations and enzyme pharmacokinetics modeling. The company has raised $15 million in Series A funding (2023) following a $4 million seed round, with backing from Tiger Global and the European Investment Bank. Algorithmiq's multiscale approach combines quantum computing and AI to revolutionize drug discovery, with recent publications on quantum algorithms for BODIPY molecules in photodynamic therapy applications and collaborations with IBM on quantum computer fine-tuning for pharmaceutical applications. 2025 Developments: The company continues to enhance its quantum software platform and developer tools in 2025. Focus remains on improving algorithm efficiency and expanding use case applications. Active engagement with the quantum developer community drives product evolution.

Categories

Key People

Sabrina Maniscalco (Co-founder, CEO), Stefan Filipp (Co-founder, CTO)